Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 10/20 | 0.51 |
| ▸ | EGFR | P00533 | 10/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.51 |
| ▸ | WEE1 | P30291 | 7/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.50 |
| ▸ | ABL1 | P00519 | 7/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.46 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.46 |
| ▸ | STAT5A | P42229 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.45 |
| ▸ | STK25 | O00506 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470067 | 0.86 | WEE1 (0.51) | SRCEGFRFGFR1WEE1PDGFRB | |
| SCHEMBL4765794 | 0.80 | MAPK14 (0.57) | SRCEGFRFGFR1WEE1PDGFRB | |
| SCHEMBL5474026 | 0.78 | MAPK14 (0.45) | SRCEGFRFGFR1WEE1PDGFRB | |
| SCHEMBL4790999 | 0.77 | MAPK14 (0.46) | SRCEGFRFGFR1WEE1PDGFRB | |
| SCHEMBL2261728 | 0.74 | WEE1 (0.52) | SRCEGFRFGFR1WEE1PDGFRB | |
| SCHEMBL11889114 | 0.70 | MAPK14 (0.49) | SRCEGFRFGFR1WEE1PDGFRB | |
| SCHEMBL5762058 | 0.70 | FGFR1 (1.00) | SRCEGFRFGFR1WEE1PDGFRB | |
| SCHEMBL22025872 | 0.69 | LCK (0.69) | EGFRPDGFRBMAPK14GAKLCK | |
| SCHEMBL11889469 | 0.69 | MAPK14 (0.46) | SRCEGFRFGFR1WEE1PDGFRB | |
| SCHEMBL11889291 | 0.68 | LCK (0.49) | EGFRPDGFRBMAPK14GAKLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481729-A1 | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases | Amgen Inc. (US) | 2012-08-01 | — | — | EP | claimed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | claimed |
| EP-1976836-B9 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-1976836-B1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2481729-A1 | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases | Amgen Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | SRC 354/4885EGFR 139/4885FGFR1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.